RxDoctor Payments Data

Lauren Littleton, PA

Medical · Sylacauga, ALNPI 1184082406

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,573 of the $1,756 with a category attached, or 89.6%. 18 manufacturers reported payments, led by AbbVie at 26.6% of the total.

$1,756in general payments, 2019–2025

Across 95 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$467
  • Astellas Pharma US Inc$305
  • Pfizer$229
  • Takeda Pharmaceuticals U.S.A., Inc.$162
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$115
  • Sumitomo Pharma America, Inc.$84
  • plus $395 from 12 others

What the payments were for

  • Food & beverage$1,57390%
  • Education$18310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,756 in reported general payments places this provider in the 65th percentile of 175 medical providers in Alabama.

See all medical providers in Alabama

Medicare billing

Part B allowed, 2024
$4,613
Medicare patients
63
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron22$12,834
VeozahFezolinetant19$10,213
Estradiol130$8,327
PremarinEstrogens, Conjugated18$8,267
YuvafemEstradiol12$2,179
ProgesteroneProgesterone, Micronized22$1,512
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst52$986
Nystatin50$892
Clobetasol Propionate28$871
Albuterol Sulfate HfaAlbuterol Sulfate29$562
Medroxyprogesterone Acetate22$561
Lidocaine12$275
Fluconazole46$266
Levothyroxine Sodium12$234
Metronidazole17$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Veozah$305$23,04741 claims
PfizerPremarin$229$8,26718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 175 medical providers in Alabama.

Other medical in Sylacauga

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →